Mabpharm Limited (HKG:2181)

Mabpharm Statistics

Total Valuation

Mabpharm has a market cap or net worth of HKD 2.10 billion. The enterprise value is 2.33 billion.

Market Cap	2.10B
Enterprise Value	2.33B

Important Dates

The next estimated earnings date is Wednesday, March 25, 2026.

Earnings Date	Mar 25, 2026
Ex-Dividend Date	n/a

Share Statistics

Mabpharm has 4.12 billion shares outstanding.

Current Share Class	4.12B
Shares Outstanding	4.12B
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	49.95%
Owned by Institutions (%)	0.00%
Float	941.30M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.53
PB Ratio	19.42
P/TBV Ratio	19.42
P/FCF Ratio	35.82
P/OCF Ratio	18.62
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 58.82, with an EV/FCF ratio of 39.75.

EV / Earnings	-77.52
EV / Sales	5.03
EV / EBITDA	58.82
EV / EBIT	n/a
EV / FCF	39.75

Financial Position

The company has a current ratio of 1.07, with a Debt / Equity ratio of 3.09.

Current Ratio	1.07
Quick Ratio	0.63
Debt / Equity	3.09
Debt / EBITDA	8.42
Debt / FCF	5.69
Interest Coverage	-2.26

Financial Efficiency

Return on equity (ROE) is -25.68% and return on invested capital (ROIC) is -3.91%.

Return on Equity (ROE)	-25.68%
Return on Assets (ROA)	-1.48%
Return on Invested Capital (ROIC)	-3.91%
Return on Capital Employed (ROCE)	-3.49%
Weighted Average Cost of Capital (WACC)	9.00%
Revenue Per Employee	1.21M
Profits Per Employee	-78,622
Employee Count	383
Asset Turnover	0.42
Inventory Turnover	0.47

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +88.89% in the last 52 weeks. The beta is 1.05, so Mabpharm's price volatility has been similar to the market average.

Beta (5Y)	1.05
52-Week Price Change	+88.89%
50-Day Moving Average	0.53
200-Day Moving Average	0.56
Relative Strength Index (RSI)	46.50
Average Volume (20 Days)	128,100

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Mabpharm had revenue of HKD 464.53 million and -30.11 million in losses. Loss per share was -0.01.

Revenue	464.53M
Gross Profit	401.37M
Operating Income	-26.15M
Pretax Income	-30.11M
Net Income	-30.11M
EBITDA	33.52M
EBIT	-26.15M
Loss Per Share	-0.01

Balance Sheet

The company has 103.18 million in cash and 334.22 million in debt, with a net cash position of -231.04 million or -0.06 per share.

Cash & Cash Equivalents	103.18M
Total Debt	334.22M
Net Cash	-231.04M
Net Cash Per Share	-0.06
Equity (Book Value)	108.33M
Book Value Per Share	0.03
Working Capital	29.90M

Cash Flow

In the last 12 months, operating cash flow was 112.98 million and capital expenditures -54.26 million, giving a free cash flow of 58.72 million.

Operating Cash Flow	112.98M
Capital Expenditures	-54.26M
Free Cash Flow	58.72M
FCF Per Share	0.01

Margins

Gross margin is 86.40%, with operating and profit margins of -5.63% and -6.48%.

Gross Margin	86.40%
Operating Margin	-5.63%
Pretax Margin	-6.48%
Profit Margin	-6.48%
EBITDA Margin	7.22%
EBIT Margin	-5.63%
FCF Margin	12.64%

Dividends & Yields

Mabpharm does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-1.43%
FCF Yield	2.79%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Mabpharm has an Altman Z-Score of -0.53 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.53
Piotroski F-Score	5